Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
5286- Ramu,    Ramucirumab efficacy in first-line gastric and esophageal cancer treatment
- Review, GC, NA
VEGFR2↓, OS↑, toxicity↝,
5268- Ramu,    A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)
- Trial, HCC, NA
other↝,
5283- Ramu,    Ramucirumab
- Review, Var, NA
VEGFR2↓,
5284- Ramu,    https://pmc.ncbi.nlm.nih.gov/articles/PMC4131847/
- Review, Var, NA
VEGFR2↓, OS↑, angioG↓, toxicity↝, ChemoSen↑, Dose↝,
5285- Ramu,  docx,    A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
- Trial, NSCLC, NA
OS↑,
5287- Ramu,    Real-Life Use of Ramucirumab in Gastric Cancer in Spain: the RAMIS Study
- in-vivo, GC, NA
VEGFR2↓, OS↑, OS↑,
5781- RES,    Resveratrol improves health and survival of mice on a high-calorie diet
- in-vivo, Nor, NA
*AntiAge↑, *IGF-1↓, *AMPK↑, *CRM↑, *PGC-1α↑, *mtDam↓, *motorD↑, *hepatoP↑, *Dose↝,
5788- RES,    Calorie restriction-like effects of 30 days of Resveratrol (resVida™) supplementation on energy metabolism and metabolic profile in obese humans
- Trial, Nor, NA
*AMPK↑, *SIRT1↑, *PGC-1α↑, *BP↓, *CRM↑, *Dose↝, *mtDam↓, *ALAT↓, *hepatoP↑,
5797- RES,    Enhancing the Delivery of Resveratrol in Humans: If Low Bioavailability is the Problem, What is the Solution?
- Review, Nor, NA
*AntiAge↑, *Dose↑, *BioAv↑, *BioAv↑, *BioAv∅, *BioAv↑, *BioAv↑, *BioAv↑, *BioAv↑,
5857- RES,  CAP,  Rad,    Resveratrol and capsaicin as safer radiosensitizers for colorectal cancer compared to 5-fluorouracil
- in-vivo, Var, NA
RadioS↑, hepatoP↝, toxicity↓,
1492- RES,    Resveratrol: Biological and pharmaceutical properties as anticancer molecule
- Review, Var, NA
RadioS↑, ChemoSen↑,
1491- RES,    Resveratrol Augments Doxorubicin and Cisplatin Chemotherapy: A Novel Therapeutic Strategy
RadioS↑, ChemoSen↑,
1490- RES,    Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues
- Review, Var, NA
TumCCA↑, ROS↑, Ca+2↑, MMP↓, ATP↓, TOP1?, P53↑, p53 Wildtype∅, Akt↓, mTOR↓, EMT↓, *BioAv↓,
1506- RES,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
DNMTs↓, BRCA1↑, HDAC↓, SIRT1↑, p300↓, survivin↓, HDAC1↓, HDAC3↓, HDAC8↓,
1489- RES,    Molecular mechanisms of resveratrol as chemo and radiosensitizer in cancer
- Review, Var, NA
RadioS↑, ChemoSen↑, *BioAv↓, *BioAv↑, Ferroptosis↑, lipid-P↑, xCT↓, GPx4↓, *BioAv↑, COX2↓, cycD1/CCND1↓, FasL↓, FOXP3↓, HLA↑, p‑NF-kB↓, BAX↑, Bcl-2↓, MALAT1↓,
1511- RES,  Chemo,    Combination therapy in combating cancer
- Review, NA, NA
eff↑, *NRF2↑, *GSH↑, *ROS↓, chemoPv↑, ChemoSideEff↓,
1282- RES,    Resveratrol Inhibits CD4+ T Cell Activation by Enhancing the Expression and Activity of Sirt1
- vitro+vivo, NA, NA
T-Cell↓, SIRT1↑, CD4+↓,
1391- RES,  BBR,    Effects of Resveratrol, Berberine and Their Combinations on Reactive Oxygen Species, Survival and Apoptosis in Human Squamous Carcinoma (SCC-25) Cells
- in-vitro, Tong, SCC25
ROS↑, eff↑,
4153- RES,    Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain
- in-vivo, AD, NA
*neuroP↑, *BDNF↑,
4154- RES,    Resveratrol improves postnatal hippocampal neurogenesis and brain derived neurotrophic factor in prenatally stressed rats
- in-vivo, AD, NA
*neuroP↑, *BDNF↑,
3612- RES,    Resveratrol in Alzheimer's disease: a review of pathophysiology and therapeutic potential
- Review, AD, NA
*other↑, *Aβ↓, *Inflam↓, *NF-kB↓, *neuroP↑, *HO-1↑, *lipid-P↓, *COX2↓, *AMPK↑, *Catalase↑, *SOD↑, *GSR↑, *ROS↓, *MMP9↓, *cognitive↑, *SIRT1↑, *IL1β↓, *IL6↓,
3613- RES,    Resveratrol for Alzheimer's disease
- Review, AD, NA
*SIRT1↑, *BioAv↝, *toxicity↓, *ROS↓, *antiOx↑, *Aβ↓, *MMP9↓, *TNF-α↓,
3614- RES,    Resveratrol--a boon for treating Alzheimer's disease?
- Review, AD, NA
*SIRT1↑, *neuroP↑,
3858- RES,    Alpha-Secretase ADAM10 Regulation: Insights into Alzheimer’s Disease Treatment
- Review, AD, NA
*neuroP↑, *antiOx↑, *LDL↓, *ADAM10↑,
3863- RES,  MEL,  VitA,RetA,    Target Enzymes Considered for the Treatment of Alzheimer's Disease and Parkinson's Disease
- Review, AD, NA - Review, Park, NA
*ADAM10↑, *ADAM10↑, *ADAM10↑,
3798- RES,    Resveratrol reverses hippocampal synaptic markers injury and SIRT1 inhibition against developmental Pb exposure
- in-vivo, NA, NA
*SIRT1↑, *BDNF↑, *PSD95↑, *memory↑,
2333- RES,    Resveratrol regulates insulin resistance to improve the glycolytic pathway by activating SIRT2 in PCOS granulosa cells
- in-vitro, Nor, NA
*glucose↓, *Insulin↓, *IGFR↓, *IGF-1↓, *LDHA↑, *HK2↑, *PKM2↑, *Glycolysis↝, *SIRT2↑,
2334- RES,    Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
- Review, Var, NA
GLUT1↓, GlucoseCon↓, lactateProd↓, Akt↓, mTOR↓, Dose↝, SIRT6↑, PKM2↓, HK2↓, PFK1↓, ChemoSen↑,
2332- RES,    Resveratrol’s Anti-Cancer Effects through the Modulation of Tumor Glucose Metabolism
- Review, Var, NA
Glycolysis↓, GLUT1↓, PFK1↓, Hif1a↓, ROS↑, PDH↑, AMPK↑, TumCG↓, TumCI↓, TumCP↓, p‑NF-kB↓, SIRT1↑, SIRT3↑, LDH↓, PI3K↓, mTOR↓, PKM2↓, R5P↝, G6PD↓, TKT↝, talin↓, HK2↓, GRP78/BiP↑, GlucoseCon↓, ER Stress↑, Warburg↓, PFK↓,
2331- RES,    Resveratrol improves follicular development of PCOS rats via regulating glycolysis pathway and targeting SIRT1
- in-vivo, Nor, NA
*LDHA↑, *PKM2↑, *SIRT1↑, *Glycolysis↝,
2330- RES,    Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission
- in-vitro, CRC, DLD1 - in-vitro, Cerv, HeLa - in-vitro, BC, MCF-7
TumCP↓, Apoptosis↑, PKM2↓, ER Stress↑,
2329- RES,    Resveratrol induces apoptosis in human melanoma cell through negatively regulating Erk/PKM2/Bcl-2 axis
- in-vitro, Melanoma, A375
P53↑, Bcl-2↓, BAX↑, Cyt‑c↑, ERK↓, PKM2↓, Apoptosis↑, γH2AX↑, Casp3↑, cl‑PARP1↑,
2328- RES,    Resveratrol Inhibits Cancer Cell Metabolism by Down Regulating Pyruvate Kinase M2 via Inhibition of Mammalian Target of Rapamycin
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7
PKM2↓, mTOR↓, GlucoseCon↓, lactateProd↓,
2650- RES,    Oxidative Stress Inducers in Cancer Therapy: Preclinical and Clinical Evidence
- Review, Var, NA
ROS↑, Dose↝, NRF2↑, NAF1↓, ChemoSen↑, BioAv↓,
2687- RES,    Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
- Review, NA, NA - Review, AD, NA
NF-kB↓, P450↓, COX2↓, Hif1a↓, VEGF↓, *SIRT1↑, SIRT1↓, SIRT2↓, ChemoSen⇅, cardioP↑, *memory↑, *angioG↑, *neuroP↑, STAT3↓, CSCs↓, RadioS↑, Nestin↓, Nanog↓, TP53↑, P21↑, CXCR4↓, *BioAv↓, EMT↓, Vim↓, Slug↓, E-cadherin↑, AMPK↑, MDR1↓, DNAdam↑, TOP2↓, PTEN↑, Akt↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, MMP7↓, MALAT1↓, TCF↓, ALDH↓, CD44↓, Shh↓, IL6↓, VEGF↓, eff↑, HK2↓, ROS↑, MMP↓,
2565- RES,    https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2007.06788.x
- in-vitro, NA, NA - in-vivo, NA, NA
AntiAg↑, TXA2↑, PKCδ↑, Dose↝,
2443- RES,    Health Benefits and Molecular Mechanisms of Resveratrol: A Narrative Review
- Review, Var, NA
*antiOx↑, *ROS↓, *PTEN↑, *Akt↓, *Catalase↑, *SOD↑, *ERK↓, *GSH↑, *AMPK↑, *FOXO1↝, *RNS↓, *Catalase↑, *cardioP↑, *PI3K↑, *eNOS↑, hepatoP↑,
2442- RES,    High absorption but very low bioavailability of oral resveratrol in humans
- in-vitro, Nor, NA
BioAv↝, Half-Life↝, BioAv↓, eff↝,
2441- RES,    Anti-Cancer Properties of Resveratrol: A Focus on Its Impact on Mitochondrial Functions
- Review, Var, NA
*toxicity↓, *BioAv↝, *Dose↝, *hepatoP↑, *neuroP↑, *AntiAg↑, *COX2↓, *antiOx↑, *ROS↓, *ROS↑, PI3K↓, Akt↓, NF-kB↓, Wnt↓, β-catenin/ZEB1↓, NRF2↑, GPx↑, HO-1↑, BioEnh?, PTEN↑, ChemoSen↑, eff↑, mt-ROS↑, Warburg↓, Glycolysis↓, GlucoseCon↓, GLUT1↓, lactateProd↓, HK2↓, EGFR↓, cMyc↓, ROS↝, MMPs↓, MMP7↓, survivin↓, TumCP↓, TumCMig↓, TumCI↓,
2568- RES,    Resveratrol: A Miracle Drug for Vascular Pathologies
- Review, Var, NA
antiOx↑, Inflam↓, cardioP↑,
2567- RES,    Neuroprotective Effects of Resveratrol in Ischemic Brain Injury
- Review, Stroke, NA
*eff↑, *neuroP↑, *antiOx↑, *Inflam↓, *cardioP↑, *AntiAg↑,
2566- RES,    A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke
- Review, Stroke, NA
*neuroP↑, *NRF2↑, *SIRT1↑, *PGC-1α↑, *FOXO↑, *HO-1↑, *NQO1↑, *ROS↓, *BP↓, *BioAv↓, *Half-Life↝, *AMPK↑, *GSK‐3β↓, *eff↑, *AntiAg↑, *BBB↓, *Inflam↓, *MPO↓, *TLR4↓, *NF-kB↓, *p65↓, *MMP9↓, *TNF-α↓, *IL1β↓, *PPARγ↑, *MMP↑, *ATP↑, *Cyt‑c∅, *mt-lipid-P↓, *H2O2↓, *HSP70/HSPA5↝, *Mets↝, *eff↑, *eff↑, *motorD↑, *MDA↓, *NADH:NAD↑, eff↑, eff↑,
2564- RES,    Effect of resveratrol on platelet aggregation by fibrinogen protection
- in-vitro, NA, NA
AntiAg↑, antiOx↓, COX2↓,
2467- RES,    Resveratrol inhibits Ca2+ signals and aggregation of platelets
- in-vitro, Nor, NA
*AntiAg↑, Ca+2↓,
2440- RES,    Resveratrol inhibits Hexokinases II mediated glycolysis in non-small cell lung cancer via targeting Akt signaling pathway
- in-vitro, Lung, H460 - in-vivo, Lung, NA - in-vitro, Lung, H1650 - in-vitro, Lung, HCC827
AntiTum↑, Glycolysis↓, HK2↓, EGFR↓, Akt↓, ERK↓, GlucoseCon↓, lactateProd↓, TumCG↓, Ki-67↓,
2439- RES,    By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice
- in-vitro, HCC, HCCLM3 - in-vitro, Nor, L02 - in-vitro, HCC, SMMC-7721 cell - in-vitro, HCC, Bel-7402 - in-vitro, HCC, HUH7
HK2↓, ChemoSen↑, other↑, Glycolysis↓, lactateProd↓, TumCP↓, Casp3↑, cl‑PARP↑, PKM2↓,
2471- RES,    Resveratrol Regulates Glucose and Lipid Metabolism in Diabetic Rats by Inhibition of PDK1/AKT Phosphorylation and HIF-1α Expression
- in-vivo, Diabetic, NA
*p‑PDK1↓, *p‑Akt↓, *Hif1a↓, *GLUT1↓,
2472- RES,    Resveratrol Restores Sirtuin 1 (SIRT1) Activity and Pyruvate Dehydrogenase Kinase 1 (PDK1) Expression after Hemorrhagic Injury in a Rat Model
- in-vivo, Nor, NA
*SIRT1↑, *PGC-1α↑, *cMyc↑, *PDK1↓,
3085- RES,    Resveratrol interrupts Wnt/β-catenin signalling in cervical cancer by activating ten-eleven translocation 5-methylcytosine dioxygenase 1
- in-vitro, Cerv, NA
TET1↑, Wnt↓, β-catenin/ZEB1↓,
3084- RES,    Resveratrol inhibits the proliferation of estrogen receptor-positive breast cancer cells by suppressing EZH2 through the modulation of ERK1/2 signaling
- in-vitro, BC, MCF-7 - in-vitro, BC, T47D
TumCP↓, EZH2↓, p‑ERK↓,

Showing Research Papers: 4551 to 4600 of 5901
Prev Page 92 of 119 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 5901

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 1,   Ferroptosis↑, 1,   GPx↑, 1,   GPx4↓, 1,   HO-1↑, 1,   lipid-P↑, 1,   NAF1↓, 1,   NRF2↑, 2,   ROS↑, 5,   ROS↝, 1,   mt-ROS↑, 1,   SIRT3↑, 1,   TKT↝, 1,   xCT↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

AMPK↑, 2,   cMyc↓, 2,   G6PD↓, 1,   GlucoseCon↓, 5,   Glycolysis↓, 4,   HK2↓, 6,   lactateProd↓, 5,   LDH↓, 1,   PDH↑, 1,   PFK↓, 1,   PFK1↓, 2,   PKM2↓, 6,   R5P↝, 1,   SIRT1↓, 1,   SIRT1↑, 3,   SIRT2↓, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 5,   Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 2,   Casp3↑, 2,   Cyt‑c↑, 1,   FasL↓, 1,   Ferroptosis↑, 1,   survivin↓, 2,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   other↑, 1,   other↝, 1,  

Protein Folding & ER Stress ⓘ

ER Stress↑, 2,   GRP78/BiP↑, 1,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   DNAdam↑, 1,   DNMTs↓, 1,   P53↑, 2,   p53 Wildtype∅, 1,   cl‑PARP↑, 1,   cl‑PARP1↑, 1,   SIRT6↑, 1,   TP53↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   CD44↓, 1,   CSCs↓, 1,   EMT↓, 2,   ERK↓, 2,   p‑ERK↓, 1,   HDAC↓, 1,   HDAC1↓, 1,   HDAC3↓, 1,   HDAC8↓, 1,   mTOR↓, 4,   Nanog↓, 1,   Nestin↓, 1,   p300↓, 1,   PI3K↓, 2,   PTEN↑, 2,   Shh↓, 1,   STAT3↓, 1,   TCF↓, 1,   TOP1?, 1,   TOP2↓, 1,   TumCG↓, 2,   Wnt↓, 3,  

Migration ⓘ

AntiAg↑, 2,   Ca+2↓, 1,   Ca+2↑, 1,   E-cadherin↑, 1,   HLA↑, 1,   Ki-67↓, 1,   MALAT1↓, 2,   MMP7↓, 2,   MMPs↓, 1,   PKCδ↑, 1,   Slug↓, 1,   talin↓, 1,   TET1↑, 1,   TumCI↓, 2,   TumCMig↓, 1,   TumCP↓, 5,   Vim↓, 1,   β-catenin/ZEB1↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EGFR↓, 2,   Hif1a↓, 2,   TXA2↑, 1,   VEGF↓, 2,   VEGFR2↓, 4,  

Barriers & Transport ⓘ

GLUT1↓, 3,  

Immune & Inflammatory Signaling ⓘ

CD4+↓, 1,   COX2↓, 3,   CXCR4↓, 1,   FOXP3↓, 1,   IL6↓, 1,   Inflam↓, 1,   NF-kB↓, 2,   p‑NF-kB↓, 2,   T-Cell↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↝, 1,   BioEnh?, 1,   ChemoSen↑, 8,   ChemoSen⇅, 1,   Dose↝, 4,   eff↑, 6,   eff↝, 1,   Half-Life↝, 1,   MDR1↓, 1,   P450↓, 1,   RadioS↑, 5,  

Clinical Biomarkers ⓘ

BRCA1↑, 1,   EGFR↓, 2,   EZH2↓, 1,   IL6↓, 1,   Ki-67↓, 1,   LDH↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   cardioP↑, 2,   chemoPv↑, 1,   ChemoSideEff↓, 1,   hepatoP↑, 1,   hepatoP↝, 1,   OS↑, 5,   toxicity↓, 1,   toxicity↝, 2,  
Total Targets: 146

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 5,   Catalase↑, 3,   GSH↑, 2,   GSR↑, 1,   H2O2↓, 1,   HO-1↑, 2,   lipid-P↓, 1,   mt-lipid-P↓, 1,   MDA↓, 1,   Mets↝, 1,   MPO↓, 1,   NQO1↑, 1,   NRF2↑, 2,   RNS↓, 1,   ROS↓, 6,   ROS↑, 1,   SOD↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↑, 1,   Insulin↓, 1,   MMP↑, 1,   mtDam↓, 2,   PGC-1α↑, 4,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   AMPK↑, 5,   cMyc↑, 1,   CRM↑, 2,   glucose↓, 1,   Glycolysis↝, 2,   HK2↑, 1,   LDHA↑, 2,   LDL↓, 1,   NADH:NAD↑, 1,   PDK1↓, 1,   p‑PDK1↓, 1,   PKM2↑, 2,   PPARγ↑, 1,   SIRT1↑, 9,   SIRT2↑, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Cyt‑c∅, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Protein Folding & ER Stress ⓘ

HSP70/HSPA5↝, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,   FOXO↑, 1,   FOXO1↝, 1,   GSK‐3β↓, 1,   IGF-1↓, 2,   IGFR↓, 1,   PI3K↑, 1,   PTEN↑, 1,  

Migration ⓘ

AntiAg↑, 4,   MMP9↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   eNOS↑, 1,   Hif1a↓, 1,  

Barriers & Transport ⓘ

BBB↓, 1,   GLUT1↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   IL1β↓, 2,   IL6↓, 1,   Inflam↓, 3,   NF-kB↓, 2,   p65↓, 1,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

ADAM10↑, 4,   BDNF↑, 3,   PSD95↑, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 4,   BioAv↑, 8,   BioAv↝, 2,   BioAv∅, 1,   Dose↑, 1,   Dose↝, 3,   eff↑, 4,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   BP↓, 2,   IL6↓, 1,  

Functional Outcomes ⓘ

AntiAge↑, 2,   cardioP↑, 2,   cognitive↑, 1,   hepatoP↑, 3,   memory↑, 2,   motorD↑, 2,   neuroP↑, 9,   toxicity↓, 2,  
Total Targets: 89

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page